Current Report Filing (8-k)
03 3월 2022 - 7:03AM
Edgar (US Regulatory)
0001591165
false
0001591165
2022-03-02
2022-03-02
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 2, 2022
H-CYTE,
INC.
(Exact
Name of Registrant as Specified in Charter)
Nevada |
|
001-36763 |
|
46-3312262 |
(State
or other jurisdiction
of
incorporation) |
|
(Commission
File
Number) |
|
(IRS
Employer
Identification
No.) |
201
E Kennedy Blvd, Suite 700
Tampa,
FL |
|
33602 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code:
(844)
633-6839
Copies
to:
Arthur
S. Marcus, Esq.
Sichenzia
Ross Ference LLP
1185
Avenue of the Americas
31st
Floor
New
York, New York
10036
(212)
930-9700
(212)
930-9725 (fax)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d 2(b)) |
|
|
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act: Common Stock
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.02. Unregistered Sales of Equity Securities
As
of March 2, 2022, 75,257,511 warrants, the resale of the underlying shares of which were registered on H-Cyte, Inc.’s (the
“Company”) Registration Statement on Form S-1 (File No. 333-262553), had been exercised, including 41,608,884 warrants
held by FWHC Bridge, LLC, an affiliate of the Company and the Company’s principal shareholder, for aggregate gross proceeds of
$1,053,605. In connection with the exercise, the holders received from the Company immediately exercisable inducement warrants (the
“Inducement Warrants”), providing for a five-year term and an exercise price of $0.014, on a one-to-one basis with the
Warrants that were exercised. The Company will use the proceeds of the warrant exercise for working capital
purposes.
The
Inducement Warrants were issued in reliance upon an exemption from registration pursuant to 4(a)(2) under the Securities Act of 1933,
as amended, and Rule 506 of Regulation D promulgated thereunder.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits.
The
following exhibit is filed as part of this report:
Exhibit
No. |
|
Description |
4.1 |
|
Form of Inducement Warrant |
104 |
|
Cover Page Interactive Data
File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
H-CYTE,
INC. |
|
|
|
Date:
March 2, 2022 |
By: |
/s/
Jeremy Daniel |
|
|
Jeremy
Daniel |
|
|
Chief
Financial Officer |
H CYTE (QB) (USOTC:HCYT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
H CYTE (QB) (USOTC:HCYT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024
H CYTE Inc (QB) (OTC 시장)의 실시간 뉴스: 최근 기사 0
More H-cyte, Inc. News Articles